Assetmark, Inc Bicycle Therapeutics PLC Transaction History
Assetmark, Inc
- $41.6 Billion
- Q2 2025
A detailed history of Assetmark, Inc transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Assetmark, Inc holds 2,073 shares of BCYC stock, worth $13,847. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,073
Previous 1,282
61.7%
Holding current value
$13,847
Previous $10,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding BCYC
# of Institutions
117Shares Held
42.4MCall Options Held
111KPut Options Held
16.6K-
Baker Bros. Advisors LP New York, NY10.9MShares$72.7 Million0.77% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.45MShares$23.1 Million6.5% of portfolio
-
Armistice Capital, LLC New York, NY2.8MShares$18.7 Million0.34% of portfolio
-
Westfield Capital Management CO LP Boston, MA2.66MShares$17.8 Million0.12% of portfolio
-
Siren, L.L.C. New York, NY2.01MShares$13.4 Million0.72% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $198M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...